12
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium Institute for Medical Research University of Sydney

Interactive Workshop “HIV Cure 101”: Challenges in identifying and

Embed Size (px)

DESCRIPTION

Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium Institute for Medical Research University of Sydney. Definitions. - PowerPoint PPT Presentation

Citation preview

Interactive Workshop

“HIV Cure 101”:Challenges in identifying and

targeting the HIV reservoir

Sarah PalmerCentre for Virus Research

Westmead Millennium Institute for Medical ResearchUniversity of Sydney

Definitions

Residual Viremia: Persistent HIV RNA measured in plasma at levels below the limit of detection of the standard clinical assay (20-50 copies/ml).

Viral Reservoir: A viral reservoir is an anatomical site or cell type in which a replication-competent form of HIV persists, accumulating with more stable properties than the circulating pool of actively replicating virus. This HIV can persist even during effective therapy.

0 200 400 600 800Time (days)

107

106

105

104

103

102

101

100

10-1

0 200 400 600 800Time (days)

107

106

105

104

103

102

101

100

10-1

Pla

sma

HIV

-1 R

NA

(co

pie

s/m

l)

22 ± 6 c/ml 4 ± 2 c/ml

Viremia Persists after Suppression by Antiretroviral Therapy

Viremia Persists after Suppression by Antiretroviral Therapy

Start Therapy (d4T/3TC/efavirenz) Start Therapy (d4T/3TC/efavirenz)

bDNA

bDNA <75 copies/ml

Single-Copy Assay

Single-Copy Assay < 1 copy/ml Palmer et al. JCM 2003Maldarelli et al. PLoS Path 2007

0 60 120 180 240 300 360

Week

Pla

sma

HIV

-1 R

NA

(cop

ies/

mL)

0.32

1

3.2

10

32

100

Biphasic decline in persistent viremia over 7 years of treatment

11.6 copies/ml

half-life=39 weeks

1.5 copies/ml

720 study assay limit720 study

Palmer et al. PNAS 2008

half-life= ∞

Persistent HIV Infection

The IAS Scientific Working Group on HIV Cure: Nature Reviews Immunology 2012Palmer et al. JIM 2011

www.aids2014.org

Persistent HIV Infection

www.aids2014.org

Measuring Persistent HIV

Where to Measure Persistent Virus?

Peripheral BloodPlasmaCells: RNA versus DNA

Tissue CompartmentsT cellsOther cell typesRNA versus DNA

Role of Replication Defective HIV

CNS/CSF

www.aids2014.org

Measuring Persistent HIV

Culture assay : IUPM

Lewin & Rouzioux, AIDS 2011Rouzioux & Richman, 2012

www.aids2014.org

Measuring Persistent HIV InfectionMeasurement Advantages Disadvantages

HIV RNA in Plasma Relatively inexpensive Difficult to separate reservoir expression vs HIV replication, some positive samples undetectable,may not be representative of intracellular HIV RNA and DNA levels

Infectious Virus: estimates the number of infectious units of HIV per million mononuclear cells (IUPM)

Only direct measurement of replication competent virus or number of proviruses capable of productive infection

Requires large quantities of cells, $$$, large error, often impossible to detect changes in reservoir size

Total HIV DNA(Peripheral Blood or Tissue Compartments)

Inexpensive, easy Unintegrated HIV DNA contributes to signal unless patients are on HAART for 1-3 years. A lot of virus is defective.

Integrated HIV DNA(Peripheral Blood or Tissue Compartments)

excludes unintegrated HIV DNA, less error than IUPM

Requires at least a million cells, complex assay, defective provirus

www.aids2014.org

Persistent HIV Infection in Tissue

CNS/CSF

Lung 100 m2

Intestine 300 m2

Pinch Biopsy 0.000003 m2

www.aids2014.org

Persistent HIV Infection in Tissues

Svicher et al. Curr HIV/AIDs Rep. 2014

www.aids2014.org

Looking Ahead

Does a “cure” require the total absence of HIV RNA and DNA?

If not, then new more sensitive assays will be needed to differentiate between replication competent and non-replicating virus.

Must all potential reservoirs be analyzed? If not, are we confident that certain reservoirs are determinative of cure/remission?

With advances in curative strategies, will our current sensitive assays provide sufficient confidence to stop HIV therapy in patients showing a near absence of HIV RNA and DNA?

Looking ahead, to determine the effectiveness of curative strategies, our field will need to develop a more standardized assay system which is sensitive, efficient, less costly, and adoptable in local settings.